We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Vildagliptin Increases Several β-Cell Function Parameters during 52-Week Treatment of Patients with Mild Hyperglycemia.
- Authors
Mari, A.; Schweizer, A.; Scherbaum, W. A.; Nilsson, P. M.; Lalanne, G.; Dunning, B. E.; Foley, J. E.
- Abstract
Vildagliptin is a potent and selective DPP-4 inhibitor that improves glycemic control in patients (pts) with type 2 diabetes (T2DM) and moderate-to-marked hyperglycemia by increasing α- and β-cell responsiveness to glucose. This randomized, placebo-controlled trial was undertaken to assess the effects of vildagliptin 50 mg qd on model-assessed β-cell function during 52-wk treatment of pts with less advanced T2DM. The study enrolled 306 mildly hyperglycemic (A1C 6.2-7.5%) T2DM pts (baseline: mean age = 63.1 y, BMI = 30.2 kg/m², FPG = 7.1 mM and A1C = 6.7%). Standard meal tests were performed at Wk 0 and Wk 52; insulin secretion rate (ISR) was calculated by C-peptide deconvolution, and β-cell function was evaluated with a model that describes ISR as a function of absolute glucose levels (insulin secretory tone and glucose sensitivity), the glucose rate of change (rate sensitivity), and a potentiation factor. Vildagliptin significantly increased insulin secretory tone (+17%), glucose sensitivity (+40%) and rate sensitivity (+32%) (figure); the potentiation factor excursion during meals was unchanged. These enhancements were accompanied by a decrease in the glucose AUC[sub 0-2h] (between-group difference = - 1.7 ± 0.5 mM⋅h, P=0.002) and in A1C (between-group difference = -0.3±0.1%, P<0.001). Conclusions: in pts with mild hyperglycemia, improved β-cell function is maintained throughout 52-wk treatment and underlies sustained improvement in glycemic control.
- Publication
Diabetes, 2007, Vol 56, pA74
- ISSN
0012-1797
- Publication type
Academic Journal